The Department of Hepatology of the University of Leipzig (ULEI) represents one of the largest hepatology units in Germany. It includes several specialized outpatient clinics with yearly presentation of > 5.000 patients, covering the whole spectrum of hepatology, hepatologic oncology and liver transplantation, a large study office with 5 full time study nurses and a research laboratory. Clinical trials are being or have been conducted ranging from phase I-IV with special focus on hepatitis B, hepatitis C, hepatocellular carcinoma, fatty liver diseases (NASH, NAFLD) and other liver diseases.
The research laboratory of the Department of Hepatology conducts numerous clinical studies as well as basic and translational scientific projects including the fields of viral hepatitis, hepatocellular carcinoma, human microbiome and genomics in hepatology. Multiple national and international cohort studies have been initiated from the section of hepatology. Every year, high ranking publications underline the strong scientific impact of the unit.
Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie, Infektiologie
Role in TherVacB
ULEI has long term experience in conduction clinical trials (phase I-IV), appropriate facilities and a well-trained staff. The university is currently involved in several translational studies and has great experience with the collection of patient materials. This includes serum, tissue and circulating blood cell (PBMC) samples, which can be collected and stored according to highest quality requirements. A special focus lies on the development of bio markers for hepatitis B virus infections. The Department of Hepatology has gained significant international reputation in the field and will contribute experience and methodology to the consortium.
ULEI has a large international network with collaborating hospitals and residents and can mobilize significant patient populations for inclusion in the clinical trials. Its experience is especially great in studies in hepatitis B, as well as in vaccine trials.
Professor & Head of the Department of Hepatology
Florian van Bömmel
Head of the Research Group Hepatitis B